Eligible pregnant individuals can receive the Abrysvo™ vaccine to help protect infants during their first RSV season.
FNHA is pleased to announce it is extending its wellness initiative from last season aimed at protecting pregnant individuals and their babies from Respiratory Syncytial Virus (RSV).
For the 2026-27 RSV season, FNHA will cover the cost of the Abrysvo™ RSV vaccine for eligible pregnant individuals, so both parent and baby can be better protected from the virus.
What is RSV?
RSV is a virus (like the common cold or the flu) that spreads quickly through coughs, sneezes and touching surfaces, usually between fall and spring. While it usually causes mild symptoms in adults, it can cause serious illness such as infections in the lungs in babies under six months.
The Abrysvo™ vaccine offers two layers of protection:
- For the pregnant parent: Strengthened immunity during RSV season.
- For the baby: Lower the likelihood of hospital visits from RSV by up to 82 per cent during their first RSV season.
Learn more about how the Abrysvo™ vaccine can help shield your baby from RSV.
Coverage Details
For the 2026-27 RSV Season, First Nations Health Benefits will cover the Abrysvo™ vaccine for eligible individuals who are between 28 and 36 weeks pregnant. This increases the eligibility window from last year.
Pharmacies can submit an online claim through Pacific Blue Cross. Please contact FNHA Health Benefits at 1-855-550-5454 with any coverage questions.
Additional Infant Protection
Limited doses of the infant antibody Nirsevimab are also available through BC Children’s Hospital for eligible infants. For infants who are not eligible to receive Nirsevimab, vaccination during pregnancy with Abrysvo™ is a recommended option to help protect babies against RSV.
Next Steps
Speak with your family doctor, nurse practitioner, community health nurse or pharmacist to learn more about RSV protection options, including Abrysvo and Nirsevimab.
